Basic Information

Strain Name
C57BL/6-Lag3tm1(LAG3)Bcgen/Bcgen
Stock Number
110013
Common Name
B-hLAG3 Mice
Source/Investigator
Bcgen (Beijing Biocytogen Co., Ltd)
Related Genes
Lag3 (lymphocyte-activation gene 3)
Species
C57BL/6
Appearance
Black
Genotypes
Homozygous

Description

The LAG3 (Lymphocyte activation gene 3, CD223) is a lymphocyte activation gene and a member of the Ig family. It is mainly expressed in activated T cells, NK cells, B cells and plasmacytoid DCs. LAG3 is a negative regulator of immunity and mainly binds to MHC class Ⅱ molecules to regulate the function of dendritic cells. The expression of LAG3 is associated with the negative immunoregulatory function of specific T cells. Inhibition of LAG3 function enhances the antitumor effect of specific CD8 + T cells, therefore LAG3 is a potential target for tumor immunotherapy.

Targeting Strategy

Details

Phenotype

Protein Expression Analysis

Splenocytes from both wild type (WT)C57BL/6 and B-hLAG3 homozygous mice were analyzed by flow cytometry. Mouse LAG3 + T cells were detectable in the WT mice, while human LAG3 + T cells were detectable in the B-hLAG3 homozygous mice. Mouse LAG3 + T cells were also detectable in the B-hLAG3 homozygous mice. The reason maybe that the anti-mouse LAG3 antibody cross-reacts with human LAG3.

Application

H

uman LAG3 mAb efficacy evaluation (MC38)

Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hLAG3 mice.
Mice were divided into control and treatment groups (n=5) when the tumor size was 150±50 mm3. Anti-hLAG3 antibody significantly inhibited tumor growth in the homozygous B-hLAG3 mice, suggesting that B-hLAG3 mouse model is an effective tool for in vivo hCD27 antibody efficacy study. The average±SEM of tumor sizes are shown in the figure.

Combination therapy of LAG3 mAb (Relatimab Analog) and mPD-1 mAb

B-hLAG3-Mice-combination-therapy-of-lag3-mab-keratimab-analog

Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hLAG3 mice. Mice were divided into control and treatment groups (n=5) when the tumor size was approximately 150 ± 50 mm3. Combination of anti-hLAG3 antibody and anti-mPD-1 antibody significantly inhibited tumor growth in the homozygous B-hLAG3 mice, suggesting that B-hLAG3 mouse model is an effective tool for in vivo hLAG3 antibody efficacy evaluation study. The average ± SEM of tumor sizes are shown in the figure.

References

1. J Exp Med. 1990 May 1;171(5):1393-405.
2.Proc Natl Acad Sci U S A. 1997 May 27;94(11):5744-9.

Back to top